Subclinical XXXX in pregnancy--occurrence and outcome.

@entity1 @entity13526 @entity281 @entity2462 @entity4092
Between the years 1972 and 1979, 40,589 pregnant @entity1 were tested for @entity2462 antibodies following suspected illness or exposure, using hemagglutination-inhibition (HI), complement fixation and staphylococcal absorption for determination of specific immunoglobulin M (IgM). Recent @entity281 was confirmed by antibody rise in paired sera and/or the presence of specific IgM. Reinfection was differentiated from primary asymptomatic @entity2462 by absence of specific IgM. Determination of neutralizing antibodies was also useful in confirming reinfections. Clinical @entity2462 was confirmed in 1,448 @entity1 (3.6%). In 154 cases asymptomatic @entity281 was detected; 98 had @entity281 and 56 experienced reinfection. In a selected group of 2,200 @entity1 exposed to confirmed @entity2462 , 6.8% had clinical @entity2462 , 3.8% @entity4092 , and in 7.1% the results were doubtful. Reinfection was detected in 12.4% of 265 @entity1 with initially low HI titers. The prospective follow-up on pregnancy outcome was available in 87 @entity1 with @entity4092 . Seven cases of @entity13526 were detected in the group of primary @entity281 , while all 25 @entity1 born following reinfection were healthy.
